Highest-materiality recent filing
Renalytix raises £11.6M in private placement and restructures $11.7M convertible bonds
Gross proceeds of £2.16M from first tranche (24M shares) and £9.43M from second tranche (104.7M shares) at £0.09 per share.
Renalytix launches £10M placing, restructures debt, plans Nasdaq delisting
Minimum £10M gross raised at 9p/share; first tranche of £2.1M closes Oct 9, second tranche conditional on shareholder vote.
Renalytix gets Nasdaq extension to Oct 25, 2024; transfers to Capital Market
Nasdaq Hearings Panel grants until October 25, 2024 to regain compliance with minimum bid price of $1.00.
Renalytix receives Nasdaq delisting notice; intends to appeal by June 28
Nasdaq determined company did not regain compliance with minimum bid price ($1.00) and MVLS ($50M) by June 19, 2024.
Medicare finalizes coverage for Renalytix's kidneyIntelX.dkd at $950/test effective Aug 1, 2024
Medicare issued final Local Coverage Determination (LCD) for kidneyIntelX.dkd; effective dates of service on/after August 1, 2024.
Renalytix Q3 revenue $0.5M; net loss $7.7M; strategic sale process initiated
Revenue of $0.5M, down from $0.7M YoY; net loss narrowed to $7.7M from $12.1M.
Renalytix enters $15M at-the-market equity offering with H.C. Wainwright
Company may sell ADSs with aggregate offering price up to $15M on Nasdaq through H.C. Wainwright.
Renalytix closes second tranche of private placement, raises ~$7M gross
Second Tranche of 26,815,841 ordinary shares at £0.20 each closed on April 24, 2024, following shareholder approval.
Renalytix president McLain resigns, Howard Doran appointed; equity offering expanded
Thomas McLain resigns as President effective April 30, 2024; severance includes 6 months base salary ($450K) and accelerated vesting of 12 months of options.
Renalytix raises $1M in registered direct offering at $0.375/share, with option for up to $3.9M
Issued 2,666,667 ordinary shares at $0.375 each for gross proceeds of approximately $1.0 million.
Renalytix raises ~$12M via two-tranche equity placing at £0.20/share
First tranche of 19,986,031 shares closes March 14, 2024, raising ~$5M gross.
Renalytix launches formal sale process after unsolicited approach from strategic diagnostic firm
Unsolicited approach from a large, publicly listed diagnostics company evaluating acquisition of all shares.
Renalytix secures 10-year US government contract; Medicare coverage decision pending
KidneyIntelX.dkd added to 10-year GWAC through GSA, covering VA, DoD, IHS, at $950/result.
Renalytix Q2 FY2024 revenue $0.7M, net loss $8.5M; CMS sets $950/test
Revenue $0.7M from KidneyIntelX (down from $1.0M YoY); no pharma services revenue.
CMS publishes draft LCD for KidneyIntelX; coverage for type 2 diabetes and CKD stages 1-3b
CMS draft LCD covers KidneyIntelX and kidneyintelX.dkd for patients with type 2 diabetes and Stage 1–3b chronic kidney disease.
NGS LCD Open Meeting scheduled for February 29, 2024 to discuss coverage of KidneyIntelX and kidneyintelX.dkd.
Study of 2,569 patients with Type 2 diabetes and DKD: KidneyIntelX deployment associated with slowed kidney function decline and improved A1C levels.
Renalytix receives Nasdaq deficiency notices for bid price and market value
ADS closing bid below $1.00 for 30+ consecutive days, violating Minimum Bid Price Requirement.
Renalytix Q1 FY2024 revenue drops 50% YoY to $0.5M; net loss $10.2M; cost cuts underway
Revenue $0.5M, down 50% from $1.0M in Q1 FY2023; net loss $10.2M vs $12.0M.
CMS sets Medicare price for Renalytix's kidneyintelX.dkd test at $950, effective Jan 2024
CMS published price for FDA-authorized kidneyintelX.dkd test on national Clinical Lab Fee Schedule at $950.
Renalytix reports FY2023 results: FDA authorization, 55% test growth, $11M cost cuts
FDA De Novo marketing authorization for KidneyIntelX.dkd to assess kidney decline risk in diabetic patients.
Renalytix expands KidneyIntelX insurance coverage with BCBSTX and Parkland Community Health Plan
BlueCross BlueShield of Texas (7M members) contract adds largest statewide health plan coverage for KidneyIntelX.
Renalytix's KidneyIntelX included in draft KDIGO 2023 chronic kidney disease guidelines
Public comment period on draft KDIGO 2023 guidelines closed; final version expected Q4 2023.
Daniel Levangie, tendered his resignation from the Company's Board of Directors and all committees effective on October 31, 2024.
announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.
announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.
On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.
On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).
On April 17, 2024, Thomas McLain notified the Company that he will resign as President of the Company, effective April 30, 2024
On April 23, 2024, the Company’s Board of Directors (the “ Board ”) appointed Howard Doran, currently the Company’s Chief Business Officer, to serve as the Company’s President, effective as of April 30, 2024.
On December 5, 2023, Dr. Chirag Parikh submitted notice of his resignation from the board of directors (the “ Board ”) of Renalytix plc (the “ Company ”), which resignation was effective immediately.
On October 18, 2023, Mr. Timothy J. Scannell submitted notice of his resignation from the board of directors (the “ Board ”) of Renalytix plc (the “ Company ”), which resignation was effective immediately.
On September 1, 2023, the Company’s Board of Directors appointed Howard Doran Jr. as the Company’s Chief Business Officer.
On June 30, 2023, Catherine Coste was appointed to the Board of Directors (the “Board”) of Renalytix plc (the “Company”).
Max materiality 1.00 · Median 0.60 · Most common event other_material